|
1
|
Jiang YF, Wu J, Chen DY. A rare case of thymic carcinoma metastasize to liver. Hepatobiliary Pancreat Dis Int 2023:S1499-3872(23)00241-2. [PMID: 38185584 DOI: 10.1016/j.hbpd.2023.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2023] [Accepted: 12/29/2023] [Indexed: 01/09/2024]
Affiliation(s)
- Yi-Fan Jiang
- Division of Hepatobiliary Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Jian Wu
- Division of Hepatobiliary Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
| | - Di-Yu Chen
- Division of Hepatobiliary Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
| |
Collapse
|
|
2
|
Nishii Y, Furuhashi K, Ito K, Sakaguchi T, Suzuki Y, Fujiwara K, Yasuma T, Kobayashi T, D’Alessandro-Gabazza CN, Gabazza EC, Taguchi O, Hataji O. Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report. Pharmaceuticals (Basel) 2022; 15:ph15070889. [PMID: 35890187 PMCID: PMC9319623 DOI: 10.3390/ph15070889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Revised: 07/08/2022] [Accepted: 07/13/2022] [Indexed: 11/22/2022] Open
Abstract
Thymic carcinoma is a rare malignant tumor with a poor prognosis. No standard treatment is currently available. The present case was a 64-year-old male smoker with no symptoms referred to our hospital because of abnormal chest radiological findings. The CT study showed a tumor between the anterior mediastinum and the right lung upper lobe, multiple nodular shadows along the right pleura, and pleural effusion. A CT-guided needle biopsy revealed squamous cell carcinoma. However, the differential diagnosis between thymic carcinoma and primary lung cancer was difficult. Treatment with carboplatin, nanoparticle albumin-bound paclitaxel, and pembrolizumab was initiated. The CT scan showed tumor shrinkage and good clinical response after four treatment cycles. Therapy was switched to maintenance therapy with pembrolizumab alone. Imaging studies showed further tumor shrinkage after twelve cycles of maintenance therapy with pembrolizumab. Sixteen cycles of maintenance therapy were continued without performance status deterioration. An abnormal radiological finding was detected after a twelve-month exacerbation-free period. The diagnosis was thymic carcinoma. Treatment with lenvatinib was initiated, and tumor-size reduction was observed. This is the first report of a case showing a successful maintenance therapy with pembrolizumab after effective first-line therapy with a combination of carboplatin-based chemotherapy plus pembrolizumab in advanced thymic carcinoma.
Collapse
Affiliation(s)
- Yoichi Nishii
- Respiratory Center, Matsusaka Municipal Hospital, Matsusaka 515-0073, Japan; (Y.N.); (K.F.); (K.I.); (T.S.); (Y.S.); (K.F.); (O.T.); (O.H.)
| | - Kazuki Furuhashi
- Respiratory Center, Matsusaka Municipal Hospital, Matsusaka 515-0073, Japan; (Y.N.); (K.F.); (K.I.); (T.S.); (Y.S.); (K.F.); (O.T.); (O.H.)
| | - Kentaro Ito
- Respiratory Center, Matsusaka Municipal Hospital, Matsusaka 515-0073, Japan; (Y.N.); (K.F.); (K.I.); (T.S.); (Y.S.); (K.F.); (O.T.); (O.H.)
| | - Tadashi Sakaguchi
- Respiratory Center, Matsusaka Municipal Hospital, Matsusaka 515-0073, Japan; (Y.N.); (K.F.); (K.I.); (T.S.); (Y.S.); (K.F.); (O.T.); (O.H.)
| | - Yuta Suzuki
- Respiratory Center, Matsusaka Municipal Hospital, Matsusaka 515-0073, Japan; (Y.N.); (K.F.); (K.I.); (T.S.); (Y.S.); (K.F.); (O.T.); (O.H.)
| | - Kentaro Fujiwara
- Respiratory Center, Matsusaka Municipal Hospital, Matsusaka 515-0073, Japan; (Y.N.); (K.F.); (K.I.); (T.S.); (Y.S.); (K.F.); (O.T.); (O.H.)
| | - Taro Yasuma
- Department of Immunology, Faculty and Graduate School of Medicine, Mie University, Tsu 514-8507, Japan; (T.Y.); (C.N.D.-G.)
| | - Tetsu Kobayashi
- Department of Pulmonary and Critical Care Medicine, Faculty and Graduate School of Medicine, Mie University, Tsu 514-8507, Japan;
| | - Corina N. D’Alessandro-Gabazza
- Department of Immunology, Faculty and Graduate School of Medicine, Mie University, Tsu 514-8507, Japan; (T.Y.); (C.N.D.-G.)
| | - Esteban C. Gabazza
- Department of Immunology, Faculty and Graduate School of Medicine, Mie University, Tsu 514-8507, Japan; (T.Y.); (C.N.D.-G.)
- Correspondence:
| | - Osamu Taguchi
- Respiratory Center, Matsusaka Municipal Hospital, Matsusaka 515-0073, Japan; (Y.N.); (K.F.); (K.I.); (T.S.); (Y.S.); (K.F.); (O.T.); (O.H.)
| | - Osamu Hataji
- Respiratory Center, Matsusaka Municipal Hospital, Matsusaka 515-0073, Japan; (Y.N.); (K.F.); (K.I.); (T.S.); (Y.S.); (K.F.); (O.T.); (O.H.)
| |
Collapse
|